Categories AlphaGraphs, Analysis, Health Care

Viking Therapeutics earnings preview: All eyes on NASH

Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. The market expects the company to report a loss of 10 cents per share during the quarter, narrower than the 14 cents per share loss it reported in the same period last year.

During the year-over quarter, net loss had increased by 14%, hurt by higher research and development expenses. As we head into the fourth quarter of this year, the clinical-stage biopharmaceutical firm is expected to see further growth in R&D expenses, which in turn, would weigh on results.

Viking therapeutics R&D

VKTX shares have gained 30% in the trailing 52 weeks. However, it has declined 60% since hitting a record peak in September last year.

Investors will be looking forward to any updates regarding the ongoing research on nonalcoholic steatohepatitis (NASH), a liver disease. Last month, Viking shares had jumped 6% after it was reported that rival Gilead Sciences’ (GILD) NASH candidate failed to meet its primary endpoint.

The stock once again received a bump when peer firm Intercept Pharmaceuticals (ICPT) produced positive topline results from the phase 3 study for its NASH drug. According to DelveInsight, the NASH market will experience significant annual growth over the 2016-2028 study period, as major-market sales increase up to $30.1 billion by 2028.

The stock has a 12-month average price target of $23, which represents a 193% upside from the last close. Hence the scope for a rally is high if the California-based firm pleases investors.

 

Earnings Transcript: Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Microsoft (MSFT) becomes a compelling buy after strong earnings, Activision deal

Microsoft Corp. (NASDAQ: MSFT) is one of the most innovative technology companies, constantly transforming the business to align with the rapidly changing digital economy. While aggressively participating in the digital

Microsoft (MSFT) Q2 revenue up 20%, earnings beat estimates

Software giant Microsoft Corp. (NASDAQ: MSFT) on Tuesday reported higher revenues and earnings for the second quarter of 2022. The results also topped expectations. At $51.7 billion, second-quarter revenues were

NFLX Stock: What the slowdown in subscriber growth means for Netflix

When online platforms thrived on the unusually strong traffic growth during the shutdown, as home-bound people turned to video-streaming and gaming sites, there was speculation that the trend might reverse

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top